Resonetics | AI Transformation Index
Resonetics is one of the most AI-durable businesses a PE investor can own: the customer outcome is a physical object that must exist in a regulated, cleanr...

Overview
Resonetics is a contract manufacturer specializing in advanced micro-manufacturing of medical device components and assemblies (laser processing, Nitinol shape-setting, microfluidic laminates, sensor technology, implantable power) for MedTech OEMs, generating revenue on a fee-for-service basis across the product lifecycle from prototyping through high-volume production.
Executive Summary
Resonetics is one of the most AI-durable businesses a PE investor can own: the customer outcome is a physical object that must exist in a regulated, cleanroom-manufactured form, and no LLM can substitute, disintermediate, or commoditize that production process. The trade-off is that Resonetics is also a low-AI-opportunity business — its production function is so physically grounded that the unrealized cognitive labor AI could compress is small. For Carlyle, the strategic implication is that Resonetics' value creation thesis should be anchored in operational excellence, platform consolidation (as evidenced by recent acquisitions), and regulatory positioning — not AI transformation, which will be incremental and peripheral rather than structurally transformative.
Durability
How resilient is this business against AI disruption?
Market Substitutability
Profit Pool Migration
Barrier to Entry
Disintermediation Exposure
Switching Costs
Opportunity
How big a deal is AI for this business?
AI Applicability
Improvement Magnitude
Transformation Upside
Domain Intelligence Amplification
54.2
Ciridae AI Score
Durability Rationale
Resonetics is structurally highly durable against AI disruption because its core value delivery is irreducibly physical: precision micro-manufacturing of safety-critical medical device components under FDA regulatory controls cannot be substituted, disintermediated, or commoditized by LLMs or AI agents. The compounding structural protections — regulatory qualification requirements, cleanroom capital intensity, vertically integrated Nitinol processing, and customer re-qualification switching costs — create a moat that is, if anything, strengthened in an AI world where cognitive barriers dissolve and physical asset ownership becomes the differentiating constraint. The primary durability risk is not AI disruption but rather the secular competitive dynamics of contract manufacturing consolidation.
Opportunity Rationale
AI represents a limited but real opportunity for Resonetics concentrated in peripheral functions: accelerating design iteration during prototyping, automating quality and regulatory documentation, improving process yield analytics, and optimizing supply chain planning. However, because Resonetics' production function is overwhelmingly physical and capital-intensive, the unrealized AI step-change is modest — there is no large cognitive workforce doing manual knowledge work at scale that AI could compress into software economics. The AI opportunity here is an operational efficiency story, not a business model transformation story.
Key Risks
Durability risk: AI-accelerated generative design tools could meaningfully compress the prototyping and product development cycle, reducing Resonetics' differentiation in early-stage customer engagement and shifting more value to OEM internal engineering teams who can design-to-manufacture specifications without Resonetics' co-development support.
Opportunity risk: The moderate engineering sophistication assessment could understate Resonetics' existing AI adoption in process optimization and quality inspection — if the company is already capturing significant AI-driven yield improvements, the remaining unrealized step-change is even smaller than assessed.
Company Overview
| Headquarters | Nashua, New Hampshire, United States |
| Products / Services | Rapid Prototyping, Product Design & Development, Manufacturing Solutions, Vertically Integrated Nitinol Solutions (Melt to Market™), Laser Processing, Metal Fabrication, Microfluidic Laminates, Sensor Technology, Medical Power, Custom Laser Systems, Cleanroom Manufacturing, Wire Stripping/Ablation, Catheter Skiving/Shaping, Laser Welding, System Design & Fabrication |
| Deal Partners | Robert Schmidt Steve Wise |
PE / Ownership History
| Event | Details |
|---|---|
Completion of Resolution Medical Acquisition by Resonetics February 2, 2026 | Arcline Investment Management sold Resolution Medical to Resonetics, which is a portfolio company of The Carlyle Group. This transaction further expanded Resonetics' capabilities and market reach. |
Announcement of Acquisition of Resolution Medical by Resonetics January 27, 2026 | Resonetics announced it signed an agreement to acquire Resolution Medical, a provider of integrated design and manufacturing solutions for complex medical devices. Resolution Medical was owned by Arcline Investment Management. The acquisition added complementary capabilities in neuromodulation, structural heart, and interventional cardiology markets. |
Acquisition of Manufacturing Assets and Process IP from Med-Ally by Resonetics January 6, 2026 | Resonetics acquired manufacturing assets, process know-how, and intellectual property related to implantable and external pulse generators from Med-Ally. This acquisition strengthened Resonetics' Medical Power business, enhancing its offerings in neuromodulation, brain-computer-interface, and cardiac rhythm management markets. |
Acquisition of SAES Medical Nitinol Business by Resonetics January 9, 2023 | Resonetics signed an agreement to acquire Memry Corporation and SAES Smart Materials, Inc. from SAES Getters S.p.A. The transaction was valued at $900 million. This acquisition expanded Resonetics' nitinol raw material and component manufacturing capabilities. The deal was backed by funds managed by Carlyle and GTCR. |
Strategic Investment in Resonetics December 3, 2021 | Funds managed by The Carlyle Group acquired a significant interest in Resonetics, valuing the company at approximately $2.25 billion. This investment marked Carlyle joining existing investor GTCR as a meaningful shareholder. |
Executives
| Name | Background |
|---|---|
Kevin D. Kelly President and CEO | Over 25 years of experience in the medical device industry. Former President of BD's Surgery Business Unit. Previous leadership roles at C.R. Bard, SmartPill, LeMaitre Vascular, and MedSource Technologies (now Integer). |
Todd Trapp Chief Financial Officer | Extensive financial leadership experience in the medical device industry. Former CFO at Abiomed and Watts Water Technologies. Previous senior financial and operational roles at Honeywell International. |
Mike Hardock Chief Commercial Officer | Strong background in medical industry sales and account management. Senior VP of Interventional Sales at Resonetics since February 2024. Previously VP of Sales and Marketing at Nordson MEDICAL. |
Kristen N. Pagano Chief Human Resources Officer | Background in human resources leadership with previous roles including Vice President of HR at BD and Senior Director of HR at CR Bard. Joined The Carlyle Group in 2024. |
Kevin Hartke Chief Technical Officer | Mayor of Chandler, Arizona. Previous roles include Director and Pastor in Chandler. Studied Biochemistry and Theology at University of Missouri-Columbia and Fuller Theological Seminary. |
David Mitchell Senior Vice President, Operations | Extensive experience in operations within the medical device manufacturing industry, particularly from his long tenure at Boston Scientific. Former Vice President, Global Supply Chain and Global Customer Experience at Boston Scientific. |
Matthew Robida Senior Vice President, Corporate Development | Nearly 15 years of experience in M&A and corporate leadership. Directs acquisition, integration, and corporate strategies at Resonetics. Previously, he held executive roles in corporate development at Tecomet, Spectrum Plastics Group, and others. |
Frédéric Borne Vice President, Fiber Optics and Power | Physics engineer with leadership in medtech manufacturing. Background in fiber optics and power technologies relevant to medical device manufacturing. |
The Carlyle Group